RT Journal Article
T1 Prospective association of liver function biomarkers with development of hepatobiliary cancers.
A1 Stepien, Magdalena
A1 Fedirko, Veronika
A1 Duarte-Salles, Talita
A1 Ferrari, Pietro
A1 Freisling, Heinz
A1 Trepo, Elisabeth
A1 Trichopoulou, Antonia
A1 Bamia, Christina
A1 Weiderpass, Elisabete
A1 Olsen, Anja
A1 Tjønneland, Anne
A1 Overvad, Kim
A1 Boutron-Ruault, Marie-Christine
A1 Fagherazzi, Guy
A1 Racine, Antoine
A1 Kühn, Tilman
A1 Kaaks, Rudolf
A1 Aleksandrova, Krasimira
A1 Boeing, Heiner
A1 Lagiou, Pagona
A1 Benetou, Vassiliki
A1 Trichopoulos, Dimitrios
A1 Palli, Domenico
A1 Grioni, Sara
A1 Tumino, Rosario
A1 Naccarati, Alessio
A1 Panico, Salvatore
A1 Bueno-de-Mesquita, H Bas
A1 Peeters, Petra H
A1 Lund, Eiliv
A1 Quirós, J Ramón
A1 Nápoles, Osmel Companioni
A1 Sanchez-Perez, Maria-Jose
A1 Dorronsoro, Miren
A1 Huerta, José María
A1 Ardanaz, Eva
A1 Ohlsson, Bodil
A1 Sjöberg, Klas
A1 Werner, Mårten
A1 Nystrom, Hanna
A1 Khaw, Kay-Tee
A1 Key, Timothy J
A1 Gunter, Marc
A1 Cross, Amanda
A1 Riboli, Elio
A1 Romieu, Isabelle
A1 Jenab, Mazda
K1 Biological markers
K1 Hepatobiliary cancer
K1 Liver function test
K1 Nested case-control study
K1 Prospective cohort
AB Serum liver biomarkers (gamma-glutamyl transferase, GGT; alanine aminotransferase, ALT; aspartate aminotransferase, AST; alkaline phosphatase, ALP; total bilirubin) are used as indicators of liver disease, but there is currently little data on their prospective association with risk of hepatobiliary cancers. A nested-case control study was conducted within the prospective EPIC cohort (>520,000 participants, 10 European countries). After a mean 7.5 mean years of follow-up, 121 hepatocellular carcinoma (HCC), 34 intrahepatic bile duct (IHBC) and 131 gallbladder and biliary tract (GBTC) cases were identified and matched to 2 controls each. Circulating biomarkers were measured in serum taken at recruitment into the cohort, prior to cancer diagnosis. Multivariable adjusted conditional logistic regression was used to calculate odds ratios and 95% confidence intervals (OR; 95%CI). In multivariable models, 1SD increase of each log-transformed biomarker was positively associated with HCC risk (OR(GGT)=4.23, 95%CI:2.72-6.59; OR(ALP)=3.43, 95%CI:2.31-5.10;OR(AST)=3.00, 95%CI:2.04-4.42; OR(ALT)=2.69, 95%CI:1.89-3.84; OR(Bilirubin)=2.25, 95%CI:1.58-3.20). Each liver enzyme (OR(GGT)=4.98; 95%CI:1.75-14.17; OR(AST)=3.10, 95%CI:1.04-9.30; OR(ALT)=2.86, 95%CI:1.26-6.48, OR(ALP)=2.31, 95%CI:1.10-4.86) but not bilirubin (OR(Bilirubin)=1.46,95%CI:0.85-2.51) showed a significant association with IHBC. Only ALP was significantly associated with GBTC risk (OR(ALP)=1.59, 95%CI:1.20-2.09). This study shows positive associations between circulating liver biomarkers in sera collected prior to cancer diagnoses and the risks of developing HCC or IHBC, but not GBTC.
YR 2016
FD 2016-01-11
LK http://hdl.handle.net/10668/9737
UL http://hdl.handle.net/10668/9737
LA en
DS RISalud
RD Apr 5, 2025